Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies

<p>Abstract</p> <p>The aim of the study is to prepare aqueous dispersions of lipid nanoparticles – flurbiprofen solid lipid nanoparticles (FLUSLN) and flurbiprofen nanostructured lipid carriers (FLUNLC) by hot homogenization followed by sonication technique and then incorporated in...

Full description

Bibliographic Details
Main Authors: Venkateswarlu Vobalaboina, Ravichandiran Velayutham, Anbu Jayaraman, Bhaskar Kesavan, Rao Yamsani
Format: Article
Language:English
Published: BMC 2009-02-01
Series:Lipids in Health and Disease
Online Access:http://www.lipidworld.com/content/8/1/6
id doaj-0225a7ccaa394b38a6b015ac5d2a3701
record_format Article
spelling doaj-0225a7ccaa394b38a6b015ac5d2a37012020-11-24T22:50:04ZengBMCLipids in Health and Disease1476-511X2009-02-0181610.1186/1476-511X-8-6Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studiesVenkateswarlu VobalaboinaRavichandiran VelayuthamAnbu JayaramanBhaskar KesavanRao Yamsani<p>Abstract</p> <p>The aim of the study is to prepare aqueous dispersions of lipid nanoparticles – flurbiprofen solid lipid nanoparticles (FLUSLN) and flurbiprofen nanostructured lipid carriers (FLUNLC) by hot homogenization followed by sonication technique and then incorporated into the freshly prepared hydrogels for transdermal delivery. They are characterized for particle size, for all the formulations, more than 50% of the particles were below 300 nm after 90 days of storage at RT. DSC analyses were performed to characterize the state of drug and lipid modification. Shape and surface morphology were determined by TEM which revealed fairly spherical shape of the formulations. Further they were evaluated for <it>in vitro </it>drug release characteristics, rheological behaviour, pharmacokinetic and pharmacodynamic studies. The pharmacokinetics of flurbiprofen in rats following application of SLN gel (A1) and NLC gel (B1) for 24 h were evaluated. The C<sub>max </sub>of the B1 formulation was 38.67 ± 2.77 μg/ml, which was significantly higher than the A1 formulation (C<sub>max </sub>= 21.79 ± 2.96 μg/ml). The C<sub>max </sub>and AUC of the B1 formulation were 1.8 and 2.5 times higher than the A1 gel formulation respectively. The bioavailability of flurbiprofen with reference to oral administration was found to increase by 4.4 times when gel formulations were applied. Anti-inflammatory effect in the Carrageenan-induced paw edema in rat was significantly higher for B1 and A1 formulation than the orally administered flurbiprofen. Both the SLN and NLC dispersions and gels enriched with SLN and NLC possessed a sustained drug release over period of 24 h but the sustained effect was more pronounced with the SLN and NLC gel</p> http://www.lipidworld.com/content/8/1/6
collection DOAJ
language English
format Article
sources DOAJ
author Venkateswarlu Vobalaboina
Ravichandiran Velayutham
Anbu Jayaraman
Bhaskar Kesavan
Rao Yamsani
spellingShingle Venkateswarlu Vobalaboina
Ravichandiran Velayutham
Anbu Jayaraman
Bhaskar Kesavan
Rao Yamsani
Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies
Lipids in Health and Disease
author_facet Venkateswarlu Vobalaboina
Ravichandiran Velayutham
Anbu Jayaraman
Bhaskar Kesavan
Rao Yamsani
author_sort Venkateswarlu Vobalaboina
title Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies
title_short Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies
title_full Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies
title_fullStr Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies
title_full_unstemmed Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies
title_sort lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, <it>in vitro, ex vivo </it>and <it>in vivo </it>studies
publisher BMC
series Lipids in Health and Disease
issn 1476-511X
publishDate 2009-02-01
description <p>Abstract</p> <p>The aim of the study is to prepare aqueous dispersions of lipid nanoparticles – flurbiprofen solid lipid nanoparticles (FLUSLN) and flurbiprofen nanostructured lipid carriers (FLUNLC) by hot homogenization followed by sonication technique and then incorporated into the freshly prepared hydrogels for transdermal delivery. They are characterized for particle size, for all the formulations, more than 50% of the particles were below 300 nm after 90 days of storage at RT. DSC analyses were performed to characterize the state of drug and lipid modification. Shape and surface morphology were determined by TEM which revealed fairly spherical shape of the formulations. Further they were evaluated for <it>in vitro </it>drug release characteristics, rheological behaviour, pharmacokinetic and pharmacodynamic studies. The pharmacokinetics of flurbiprofen in rats following application of SLN gel (A1) and NLC gel (B1) for 24 h were evaluated. The C<sub>max </sub>of the B1 formulation was 38.67 ± 2.77 μg/ml, which was significantly higher than the A1 formulation (C<sub>max </sub>= 21.79 ± 2.96 μg/ml). The C<sub>max </sub>and AUC of the B1 formulation were 1.8 and 2.5 times higher than the A1 gel formulation respectively. The bioavailability of flurbiprofen with reference to oral administration was found to increase by 4.4 times when gel formulations were applied. Anti-inflammatory effect in the Carrageenan-induced paw edema in rat was significantly higher for B1 and A1 formulation than the orally administered flurbiprofen. Both the SLN and NLC dispersions and gels enriched with SLN and NLC possessed a sustained drug release over period of 24 h but the sustained effect was more pronounced with the SLN and NLC gel</p>
url http://www.lipidworld.com/content/8/1/6
work_keys_str_mv AT venkateswarluvobalaboina lipidnanoparticlesfortransdermaldeliveryofflurbiprofenformulationitinvitroexvivoitanditinvivoitstudies
AT ravichandiranvelayutham lipidnanoparticlesfortransdermaldeliveryofflurbiprofenformulationitinvitroexvivoitanditinvivoitstudies
AT anbujayaraman lipidnanoparticlesfortransdermaldeliveryofflurbiprofenformulationitinvitroexvivoitanditinvivoitstudies
AT bhaskarkesavan lipidnanoparticlesfortransdermaldeliveryofflurbiprofenformulationitinvitroexvivoitanditinvivoitstudies
AT raoyamsani lipidnanoparticlesfortransdermaldeliveryofflurbiprofenformulationitinvitroexvivoitanditinvivoitstudies
_version_ 1725673572452532224